In a study, approximately 64% of patients with gastrointestinal stromal tumors (GISTs) reported experiencing cancer-related cognitive impairments, commonly known as “chemo brain” or “chemo fog.” This is particularly noteworthy, given the improved overall survival rates for GIST patients due to effective tyrosine kinase inhibitor therapies. The study, which involved an online survey completed by 485 GIST patients (average age of 58 years and median time of 5 years since diagnosis), aimed to evaluate the impact of cognitive impairments on their quality of life. It also examined other symptoms like anxiety, depression, fatigue, sleep quality, and pain interference. Results indicated that patients with GIST for over five years suffered more severe cognitive impairments than those with a more recent diagnosis.
The study suggests that the tumor or the body’s reaction to it might be responsible for these impairments, although these conclusions are based on self-reported data rather than objective neurocognitive testing. Researchers noted the future possibility of using cognitive behavioral therapies to improve the quality of life for GIST survivors, who are now living longer due to successful treatments, emphasizing the need for further research into non-drug, cognitive behavioral therapies to enhance the health-related quality of life for these patients.
Reference: Lankas M. Many Survivors of GISTs, a Rare Cancer, May Experience Cancer-Related Cognitive Impairments After Treatment. CURE. Published October 5, 2022. Accessed February 5, 2024. https://www.curetoday.com/view/many-survivors-of-gists-a-rare-cancer-may-experience-cancer-related-cognitive-impairments-after-treatment
